Exploration of piperidinols as potential antitubercular agents

Article abstract of DOI:10.3390/molecules191016274

Novel drugs to treat tuberculosis are required and the identification of potential targets is important. Piperidinols have been identified as potential antimycobacterial agents (MIC < 5 μg/mL), which also inhibit mycobacterial arylamine N-acetyltransferas

Full text of DOI:10.3390/molecules191016274

Molecules 2014, 19, 16274-16290; doi:10.3390/molecules191016274
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Exploration of Piperidinols as Potential Antitubercular Agents
Areej Abuhammad 1,2, Elizabeth Fullam 1,3,4, Sanjib Bhakta 1,†, Angela J. Russell 1,3,
Garrett M. Morris 5, Paul W. Finn 5,7 and Edith Sim 1,6,
*
1
Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan,
Queen Rania Street, Amman 11942, Jordan
2
3
Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road,
Oxford OX1 3TA, UK
4
5
6
School of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
InhibOx, Oxford Centre for Innovation, New Road, Oxford OX1 1BY, UK
Faculty of Science, Engineering and Computing, Kingston University, Penrhyn Road,
Kingston KT1 2EE, UK
7
Department of Applied Computing, University of Buckingham, Hunter Street,
Buckingham MK18 1EG, UK
†
Present address: Department of Biological Science, Birkbeck College, University of London,
Malet Street, London WC1E 7HX, UK.
* Author to whom correspondence should be addressed; E-Mail: E.Sim@kingston.ac.uk;
Tel.: +44-20-8417-2492; Fax: +44-20-8417-2972.
External Editor: Jean Jacques Vanden Eynde
Received: 14 July 2014; in revised form: 9 September 2014 / Accepted: 24 September 2014 /
Published: 10 October 2014
Abstract: Novel drugs to treat tuberculosis are required and the identification of potential
targets is important. Piperidinols have been identified as potential antimycobacterial agents
(MIC < 5 μg/mL), which also inhibit mycobacterial arylamine N-acetyltransferase (NAT),
an enzyme essential for mycobacterial survival inside macrophages. The NAT inhibition
involves a prodrug-like mechanism in which activation leads to the formation of bioactive
phenyl vinyl ketone (PVK). The PVK fragment selectively forms an adduct with the cysteine
residue in the active site. Time dependent inhibition of the NAT enzyme from
Mycobacterium marinum (M. marinum) demonstrates a covalent binding mechanism for all
inhibitory piperidinol analogues. The structure activity relationship highlights the

Molecules 2014, 19
16275
importance of halide substitution on the piperidinol benzene ring. The structures of the NAT
enzymes from M. marinum and M. tuberculosis, although 74% identical, have different
residues in their active site clefts and allow the effects of amino acid substitutions to be
assessed in understanding inhibitory potency. In addition, we have used the piperidinol
3-dimensional shape and electrostatic properties to identify two additional distinct chemical
scaffolds as inhibitors of NAT. While one of the scaffolds has anti-tubercular activity, both
inhibit NAT but through a non-covalent mechanism.
Keywords: tuberculosis; covalent inhibitors; piperidinols; arylamine N-acetyltransferase
1. Introduction
Although tuberculosis (TB) is treatable with well-established drugs, and even preventable through
vaccination, the disease remains one of the leading causes of death by bacterial infection, being
responsible for approximately two million deaths annually. Tuberculosis infects one-third of the human
population. It is estimated that 8.6 million new infections occurred in 2012, and thus it affects more
people today than at any other time in history [1,2]. Until very recently TB has not been in the research
portfolios of most of the major pharmaceutical companies. This neglect is partly because the greatest
burden of disease is in developing countries [2]. A significant proportion of TB cases and deaths occur
in human immunodeficiency virus (HIV) positive people [2].
The current drug treatment is more than 40 years old, while the vaccine is almost 100 years old.
Although the existing TB treatment is effective against drug-susceptible bacilli, the continuation of
treatment for at least six months is essential in order to kill persistent or slow growing strains [3]. The
emergence of multi-drug resistant (MDR) and extensively-drug resistant (XDR) TB further adds to the
burden [4] and requires treatment with second-line drugs, which are less effective, more toxic, and
expensive. Recently totally-drug-resistant TB (TDR) has been reported [5,6].
Bedaquiline (TMC-207), which inhibits mycobacterial ATP synthase, was approved by the FDA as
part of the treatment regimen for MDR-TB [7,8]. Thus, it is the first new TB drug since the introduction
of rifampin in 1970 [9].
Although the availability of the M. tuberculosis genome and the identification of potential targets are
leading to filling of the drug pipeline with agents such as benzothiazinones [10], new targets need to be
identified to avoid the problem of drug resistance in the future. The need for the physicochemical
properties of potential compounds also needs to be addressed to allow penetration of the uniquely
impermeable cell envelope, and to find an escape from active drug efflux mechanism in mycobacteria.
There is a history of the use of pro-drugs as anti-mycobacterials. Isoniazid, the front-line
anti-tubercular, is a pro-drug, which is activated within the bacterium [11] and acts through a covalent
binding mechanism within M. tuberculosis. Traditionally, medicinal chemists have been skeptical about
covalent drugs because of concern regarding potential for off-target reactivity. However, there has
recently been a resurgence of interest in covalent drugs, with their potential advantages being increasingly
recognized [12].

Molecules 2014, 19
16276
Compound 1, a piperidinol derivative, has been identified as a potent antimycobacterial
(MIC < 5 μg/mL) which also inhibits mycobacterial arylamine N-acetyltransferase (NAT) (Figure 1)
through a covalent mechanism of action [13]. The NAT enzyme in mycobacteria has been identified in
several studies as a potential target for the treatment of tuberculosis in that the gene is part of a cluster
essential for M. tuberculosis survival inside macrophage [14–16]. MMNAT (NAT enzyme from
Mycobacterium marinum), at 74% identical has been exploited as a model for M. tuberculosis NAT
(TBNAT) since the MMNAT enzyme is highly soluble and a crystal structure has been available for
some time. Although recently a preparation of TBNAT and a crystal structure have been available, the
protein from M. tuberculosis is much more difficult to handle and particularly in relation to obtaining
the high concentrations which best support crystallization.
Compound 1 has previously been investigated as a candidate for several therapeutic uses, including
anti-inflammatory [17], anticancer [18], anticonvulsant [19], antimicrobial [20] and historically as an
antitubercular [21]. Furthermore, compound 1 is a cyclic derivative of a Mannich-base that has been
investigated as a prodrug vehicle for several therapeutic agents [22]. Understanding the key features of
this scaffold is essential in progressing the development of the compound as a therapeutic agent.
Figure 1. Specificity of 1 for prokaryotic N-acetyltransferase (NAT) enzymes.
Compound 1 was tested at 30 μM against five pure recombinant NAT enzymes from M. smegmatis (MSNAT),
S. typhimurium (STNAT), P. aeruginosa (PANAT) and also against two eukaryotic enzymes, hamster NAT2
(shNAT2) and human NAT1. The NAT activity assay [23] was used to determine the specific activities of the
pure recombinant NATs in the presence of compound 1. The results are shown as the mean ± S.D. of triplicate
determinations of percentage inhibition of hydrolysis of Ac-CoA as described in the presence of 500 μM
5-amino salicylic acid (5ASA) as substrates for all enzymes apart from TBNAT where 500 μM hydralazine (HLZ)
has been used as a substrate. The inhibition is represented as a percentage compared to an uninhibited control.
To this end, we report the evaluation of chemical modifications on the piperidinol scaffold using
inhibition of mycobacterial NAT by compound 1 and its analogues in order to try to improve potency.
We have also carried out in silico studies with the piperidinol scaffold as a query molecule to open up
chemical space on the basis of 3D shape and electrostatics and have identified two new chemical
scaffolds, which were subsequently found to be NAT inhibitors. We have investigated the compounds
as inhibitors of mycobacterial growth.

Molecules 2014, 19
16277
2. Results and Discussion
2.1. Mechanism of Inhibition
Compound 1 has been identified as a selective inhibitor for bacterial and mycobacterial NATs [24,25].
The mechanism of NAT inhibition by this compound and its analogues has been elucidated and involves
specific and unique covalent modification of the active site cysteine of NAT [13] (Figure 2).
Figure 2. The mechanism of adduct formation.
The adduct formation is proceeded by the formation of a reactive phenyl vinyl ketone (PVK). The PVK reaction
with thiols resulted in the addition of a 3-Phenyl-3-oxopropyl moiety (POP) (when R1 is H) or a
3-(4-Chlorophenyl)-3-oxopropyl moiety (when R1 is Cl). The expected differences in molecular weight of the
added fragments are +132.07 Da and +166 Da, respectively.
The NAT enzyme from M. marinum is 74% identical to NAT from M. tuberculosis and the M. marinum
NAT enzyme has been studied as a model for the less stable M. tuberculosis enzyme [13,26,27].
Using a selected set of compound 1 analogues (Table 1), the inhibition was demonstrated to be
irreversible and time-dependent using the recombinant NAT enzyme from M. marinum, MMNAT, as
has previously been described for inhibition of NAT from M. tuberculosis [13] (Table 1 and Figure S1
in Supplementary Materials). To facilitate comparison of the compounds, the values of the apparent
inactivation half-life of the enzyme were calculated in the presence of the different compounds from kobs
as shown in Table 1. Potent inhibitors are predicted to exhibit a shorter inactivation half-life [28]. An
adduct is formed, in which a phenyl vinyl ketone moiety (PVK) is directly conjugated to the active site
cysteine sulfhydryl group [13]. For compounds 2, 3 and 5, the structure of the inhibitor has a halide
substituent on the para position of the benzene ring (position R1, Table 1), and thus the adduct formed
with the active site cysteine is predicted to be larger than the benzene ring unsubstituted at the para
position, as is observed by mass spectroscopy analysis [13].
The piperidinols exhibited the same type of inhibition against the homologue of NAT from
M. tuberculosis, TBNAT, which is 74% identical in sequence to MMNAT and shares the key features
of the binding pocket. Whilst the inhibition was more rapid with TBNAT than with MMNAT, higher
concentrations of inhibitor were required compared to those used with MMNAT. The mechanism of
activation of the compounds have been described in Abuhammad et al., 2012 and is proposed to procede
by a nucleophilic attack on the piperidinol ring carbonyl. We have not been able to ascertain whether
the activation is enzyme catalyzed or is due to hydrolysis within the binding pocket. However, it is likely

Molecules 2014, 19
16278
that the binding of the compounds into the active site promote the formation of the active intermediate
since only the active site Cys is modified. If the active species were formed through hydrolysis without
binding to the enzyme a priori, this would be likely to result in a random modification of all of the
cysteine residues.
Table 1. The time-dependent activity of the piperidinols against MMNAT.
Critical Volume
Code
R1
R2
kobs (10−3 min−1)
t1/2 (min)
cLogP
(cm3/mol)
1
2
3
4
5
6
H
Cl
Br
H
-CH3
-CH3
9 ± 2
110 ± 2
74 ± 7
81.5
6.3
864.5
2.41
3.53
4.07
2.75
3.07
3.66
962.5
-CH3
9.4
988.5
-CH2CH3
-CH2CH3
-(CH2)3CH3
15 ± 1
45.6
1.1
920.5
F
638 ± 120
104 ± 8
956.5
H
6.6
1032.5
7
8
9
H
H
H
573 ± 25
10 ± 1
1.2
71.4
4.2
1077.5
1092.5
994.5
3.96
4.15
2.84
163 ± 39
10
11
H
H
19 ± 1
34 ± 1
37.1
20.2
1017.5
1276.5
0.91
3.06
The assay was performed as described in Methods and kobs values were obtained from the slope of the
semi-logarithmic plots of the residual activity vs. incubation time at 11.9 μM except for 5, 7 and 11 (5.9 μM)
and 10 (23.8 μM). The results are presented as the mean ± S.D. of triplicate measurements at 24 °C. t1/2 is the
apparent inactivation half-life calculated from kobs (t1/2 = 0.693/kobs). The critical volumes (the volume of one
mole of material at the critical temperature and pressure) and cLogP values (the octanol-water partition
constant) as predicted by ChemBioDraw Ultra 12.0 [29] are shown. Compounds 1, 2, 7 and 11 have been
described previously [13] and are included for full comparison.
2.2. Effects of Substitutions on the Piperidinol Scaffold
When the phenyl ring was para substituted with a halide, the resulting piperidinols (2, 3 and 5)
displayed an increase in the inactivation potency as evidenced by the shorter inactivation half time (Table 1)

Molecules 2014, 19
16279
than the benzene ring unsubstituted at the para position. The fluoro derivative (5) showed a low
inactivation time (Table 1). The ethyl substituent on the nitrogen atom in 5 is likely to contribute to the
increased inactivation potency since the ethyl piperidinol 4 with no halide substituent, shows twice the
activity of the methyl derivative 1. However, other factors, for example the chemical stability of the
compounds, could well contribute to their relative protein inactivation activities.
Increasing the length of the alkyl chain on the piperidinol nitrogen results in increased inhibition
(as measured by the rate; Table 1; compounds 1, 4 and 6). However, this is unlikely to be due to
hydrophobicity alone, because there is a significant difference in activity between the potent cyclohexyl
analogue, compound 7, and the weak benzyl analogue, compound 8, despite both compounds having
similar clogP values (Table 1, Figure S2 in Supplementary Materials). The cyclohexyl ring has a strong
preference to adopt a chair conformation whilst the ring of the phenyl is planar. Furthermore, the extra
methylene in the benzyl group inserts two rotatable bonds not present in the cyclohexyl compound,
making it more conformationally flexible, as well as significantly altering the geometry of the
attachment. Either of these points could contribute to reduced activity of the benzyl compound despite
increased bulk.
Although there is no simple correlation with hydrophobicity, it appears to be important since highly
polar R2 substituents result in poor inhibition of MMNAT. In addition to hydrophobicity factors, the
volume of the inhibitors appears to be a contributing factor to inhibitory potency (Table 1). Except for
compounds 3, 7 and 10, the inhibitor potency was found to increase linearly as the critical molar volume
of the molecule increased (Table 1).
2.3. Comparison of MMNAT and TBNAT
TBNAT and MMNAT, although being 74% identical in sequence, show different substrate and
inhibition profiles [30]. To provide a basis for a qualitative comparison of MMNAT and TBNAT
inhibition by the piperindols, IC50 analyses were carried out. The IC50 values were comparable for
inhibitors 1–6 and 11; however, there is a difference between the activities of inhibitors 8–10 when
tested against MMNAT compared with TBNAT (Table 2).
Evidence for binding of the piperdinols in close proximity to the methionine moieties Met209 and
Met222 of MMNAT can be deduced from structural studies on the MMNAT complexed with
compound 1 [31]. The refinement the crystal structure of MMNAT soaked with compound 1, shows
patches of electron density, contiguous with the methionine residues (Met209 and Met222) and the
tryptophan Trp97, indicating the presence of a bound chemical entity(ies). The aromatic rings and the
methylamine moiety of 1 have been modelled into these electron density patches (hypothetical model,
Figure S3, Supplementary Materials). Notably, this electron density was absent in all other MMNAT
structures (PDB entries 2vfb, 2vfc [32]; and 3ltw [27]), excluding the possibility that it was due to
components from the expression system or from the crystallization cocktail as has been observed in e.g.,
NAT from Bacillus anthracis [33]. The interpretation of the electron density is proposed to be caused
by the presence of the ligand in the enzyme’s active site before activation into the reactive intermediates.
It is proposed that once the piperidinol is activated to the PVK fragment (Figure 2) the fragment is likely
to react immediately with the active site cysteine. It is possible that the piperidinol fragment may be
activated by the enzyme acting as a catalyst despite the relatively acidic pH (6.5) at which the crystals

Molecules 2014, 19
16280
grew, as the enzyme was shown to maintain a stable catalytic (acetyl-transfer) activity within a pH range
of 6–9. However, further evaluation of the pH stability of the piperidinols would need to be pursued for
drug design.
Therefore, we hypothesize that the piperidinols bind at this location within the MMNAT binding
pocket. This region within the binding pocket varies significantly between MMNAT and TBNAT [34]
(Figure 3) and is likely to explain the difference in the inactivation rate of these inhibitors on both
enzymes (Table 2). The binding pocket of the TBNAT appears to be more charged and polar, compared
to that of MMNAT [34]. The two methionine residues (Met209 and Met222) within this region of the
binding pocket in MMNAT are substituted with tyrosine and serine in TBNAT, whilst the two leucine
residues (Leu98 and Leu151) and methionine (Met133) are substituted with lysine, histidine and
glutamine, respectively (Figure 3). This architecture is proposed to explain the reduced affinity of the
piperidinols for TBNAT as evidenced by the need for higher concentrations to inhibit the TBNAT,
although the rate of inactivation with TBNAT is faster than with MMNAT.
Figure 3. Comparison of the binding pockets of TBNAT and MMNAT. A ribbon
representation shows the main residues in the binding pocket of (A) TBNAT and (PDB code
4BGF, 2.1 Å) and (B) MMNAT (PDB code 2VFB; 2.1 Å).
2.4. Effect on Mycobacteria
The compounds were also assessed for in vitro anti-mycobacterial activity against M. bovis BCG and
the M. tuberculosis strain H37Rv (Table 2). All nine compounds showed promising antimycobacterial
activity against M. tuberculosis, with an MIC below 10 μg/mL (Table 2).
In the absence of experimental evidence on comparison of uptake into M. tuberculosis and M. bovis
BCG it is not possible to speculate on the reason for the minor differences. Nevertheless, the fact that
these compounds do have activity in inhibiting growth identifies that they are of interest.

Molecules 2014, 19
16281
Table 2. The inhibitory activity of compound 1 and its analogues a.
TBNAT
MMNAT
MIC (μg/mL)
Code
R1
R2
IC50 (μM)
HLZ
IC50 (μM)
HLZ
IC50 (μM)
5ASA
% Inhibition
% Inhibition
M. bovis BCG
M. tuberculosis
1
2
3
4
5
6
H
Cl
Br
H
-CH3
-CH3
101 ± 1
98 ± 1
98 ± 3
72 ± 4
108 ± 1
100 ± 3
7.7 ± 0.9
1.6 ± 0.1
2.9 ± 0.4
7.3 ± 0.3
4.4 ± 0.0
6.9 ± 0.4
105 ± 1
103 ± 2
99 ± 1
1.3 ± 0.0
0.16 ± 0.01
0.08 ± 0.01
1.9 ± 0.0
0.5 ± 0.0
2.6 ± 1
6.0 ±1
6.3–12.5
6.3–12.5
6.3–12.5
6.3–12.5
6.3–12.5
6.3–12.5
1–10
ND
1.4 ± 0.6
1.3 ± 0.4
8.0 ± 1
-CH3
5–10
5–10
5–10
1–5
-CH2CH3
-CH2CH3
-(CH2)3CH3
126 ± 5
102 ± 3
102 ± 3
F
1.3 ± 0.5
5.0 ± 0.4
H
7
8
H
H
72 ± 60
58 ± 2
4.4 ± 0.1
ND
103 ± 1
101 ± 1
ND
1.7 ± 0.2
ND
6.3–12.5
6.3–12.5
1–5
0–1
4.1 ± 0.4
9
H
51 ± 3
ND
100.8 ± 0.5
2.5 ± 0.3
9.0 ± 0.9
ND
0–1

Molecules 2014, 19
16282
Table 2. Cont.
TBNAT
MMNAT
MIC (μg/mL)
Code
R1
R2
IC50 (μM)
IC50 (μM)
IC50 (μM)
% Inhibition
% Inhibition
M. bovis BCG
M. tuberculosis
HLZ
HLZ
5ASA
10
H
47 ± 2
67 ± 4
ND
99 ± 0.7
13 ± 1
>30
3.1–6.3
ND
11
H
1.1 ± 0.3
100 ± 2
2.7 ± 0.4
1.1 ± 0.3
6.3–12.5
1–5
a NAT activity was measured by a NAT-inhibition assay using 150 μM HLZ and 120 μM Ac-CoA as substrate. The percentage of enzyme inhibition was measured in the
presence of 50 μM inhibitor and compared to the un-inhibited control. The IC50 values were determined by measuring the enzyme activity in the presence of variable
concentrations of each inhibitor (0–250 μM) and compared to the un-inhibited control. The results are presented as the mean ± S.D. of triplicate measurements. ND is not
determined. Inhibition curves were obtained by non-linear fitting of the% inhibition and the inhibitor concentration (μM) using the Log(inhibitor) vs. response module of
GraphPad Prism 5.0.

Molecules 2014, 19
16283
2.5. In Silico Screening
The piperidinols are chiral molecules and the identification of other active chemotypes is desirable.
Previously, ligand-based virtual screening for NAT inhibitors based on the 3D shape of compound 1 has
proven very useful for identifying inhibitors of a distinct NAT homologue in humans [35]. Since then, a
new methodology (ElectroShape) has been developed which includes an electrostatic comparison in the
molecular similarity description in addition to shape [36,37]. Importantly, given the chiral nature of the
query molecule, the molecular representation used by ElectroShape is sensitive to chirality, which was
not the case in the previous work [38]. Screening for novel NAT inhibitors based on the 3D shape and
electrostatic comparison of compound 1 was performed using the ElectroShape approach. A conformational
model was generated for compound 1 after which it was used as a search query against a database of
7.3 million commercially-available molecules, Scopius (InhibOx Ltd., Oxford, UK). The identified hits
were ranked based on the ElectroShape score and 12 compounds out of the top 100 hits were purchased
and tested for their NAT inhibition activity. The chemical structures of the tested molecules and their
inhibition activities are shown in Table S1 in Supplementary Materiala. Among these inhibitors,
compounds 15 and 16 show NAT inhibition activities (Figure 4 and Figure S4 in Supplementary
Materials). Although both 15 and 16 show high potency against MMNAT, only compound 15 shows
inhibition of TBNAT.
Figure 4. Active hits obtained by in silico 3D-shape screening.
The ability to identify inhibitors based on the 3D shape and electronic properties of compound 1
supports the affinity of the intact piperidinols to the NAT binding pocket substantiates, but does not
prove, that the binding of the compounds into the active site promote the formation of the active
intermediate. Although the search query molecule 1 acts via covalent bond formation, the hits obtained
show no covalent adduct formation as was confirmed by mass spectroscopy analysis (data are not
shown). Interestingly, compound 15 shows also antimycobacterial activity with MIC of 125–250 μM
(33–66 µg/mL) against M. bovis BCG (Figure S5 in Supplementary Material).
3. Experimental Section
All chemicals and reagents were purchased from Sigma Aldrich (Poole, Dorset, UK), unless
otherwise stated. Data analysis was carried out using GraphPad Prism 5.0. The critical volumes and

Molecules 2014, 19
16284
cLogP values were predicted by ChemBioDraw Ultra 12.0 [29]. Structural figures and graphical
renderings were made with Discovery Studio (DS) Visualizer 3.1 [39].
3.1. Range of Inhibitors
Compound 1 which was identified from a previous high throughput screen was synthesized ab initio
to confirm its identity and activities as previously described [40]. It has been confirmed separately that
during the cyclisation only the diastereoisomer 1 depicted in Scheme 1 was formed [40]. The compound
was obtained in 79% yield, with greater than 99.5% purity as determined by reverse phase HPLC.
Scheme 1. Reagents and conditions: (i) MeNH2·HCl, paraformaldehyde, cat. ZnCl2, MeCN,
Δ, 16 h; (ii) NaOH.
Halogenated analogues 2 and 3 were either purchased from Chembridge, (San Diego, CA, USA)
(compound 2) or synthesized by cyclisation of the intermediate bis-Mannich bases with NaOH, which
following recrystallization of the products furnished the corresponding piperidinols (compound 3;
Scheme 1).
To investigate further the structural influence of N functionality over both NAT inhibition and
antimycobacterial activity, eight commercially available compounds (4–11, Cheshire Biosciences,
Chester, UK) with different substitutions at the piperidinol nitrogen were selected for testing. All
compounds were the best available grade. All compounds were greater than 95% pure apart from
compound 4, which was only 80% pure. Stock solutions of the all compounds were prepared at
5–50 mM in DMSO and stored at −20 °C.
3.2. Enzyme Production
The NAT enzymes from M. smegmatis [41], S. typhimurium [42], P. aeruginosa [43], M. marinum [32],
M. tuberculosis [44], hamster NAT2 [45] and human NAT1 [46] were produced as recombinant proteins,
purified as previously described and stored at −80 in 20 mM Tris-HCl pH 8 containing 1 mM
dithiothreitol and 5% glycerol and thawed and used within 1–5 h.
3.3. NAT Inhibition Assay
An assay for measuring the formation of CoA [23] was modified and used to determine the activity
of the enzyme in the presence of potential inhibitors exactly as described previously [13]. Irreversible

Molecules 2014, 19
16285
inhibition, progressive with time was measured for the piperidinol inhibitors by the protocol described
in [13] and the values of the apparent first order rate constant (kobs) were determined using the Kitz and
Wilson model [28]. Adduct formation was determined as previously described by mass spectroscopy
analysis [13].
3.4. Mycobacterial Growth Inhibition in Vitro
Mycobacterial growth inhibition was measured in one of two ways: on agar and in liquid culture.
Mycobacteria (M. bovis BCG and M. tuberculosis H37Rv) were grown as spot cultures in
6-well plates on solid medium (Middlebrook 7H10 medium supplemented with 10% (v/v) oleic
acid-albumin-dextrosecatalase (OADC)) as previously described [14,47], with test compounds at the
concentrations indicated in the text. Test compounds were added to the melted, partially cooled
7H10-OADC agar medium as solutions in DMSO, and the final concentration of DMSO in each well
was 0.1% (v/v). The minimum inhibitory concentration (MIC) is defined as the concentration of inhibitor
at which no growth of mycobacteria was detected after a period of 2 weeks. Compound 1 and its
analogues that showed MIC below 5 μg/mL (6–9 and 11; Table 2) were tested in vitro for their cytotoxic
effect on RAW 264.7 cells as previously described [48] and no cytotoxicity was observed at up to
50 μg/mL inhibitor concentration.
3.5. Alamar Blue Assay
The Alamar blue assay was used to determine the antimycobacterial activity of NAT inhibitors
against M. bovis BCG str. Pasteur (ATCC 35734) [49,50].
M. bovis BCG (100 mL) was grown until early log-phase (OD600 0.4–0.7). The cells were harvested
(2500 g, 15 min), resuspended (50 mL phosphate-buffered saline (PBS), 0.05% Tween 80) and harvested
(25,000 g, 15 min). The cells were resuspended (4 mL PBS, 0.05% Tween 80), aliquoted (100 μL) per
cryo-tube and snap frozen in liquid nitrogen and stored at −80 °C. 7H9GC-OADC (2.4 mL) was added
to 100 μL of cells and diluted 100-fold in 7H9GC-OADC. The assay was carried out in 96-well plates
in the presence of either compound 4, and INH as control (0–66 μg/mL in DMSO). Plates were incubated
at 37 °C in the case of M. bovis BCG. Alamar Blue dye (50 μL) was added after six days for M. bovis
BCG. The minimum inhibitory constant (MIC) was determined visually at the concentration at which
color-change occurred (blue to pink).
3.6. In Silico Shape-Based Screening
In silico screening for potential NAT inhibitors was performed using the ElectroShape approach [37].
ElectroShape requires as input a three-dimensional representation of the query molecule, compound 1.
Because of the uncertainties around the specific bioactive conformation, a conformational model was
constructed which consists of a representative set of low-energy conformations. Conformations were
generated using the program Conform [51] keeping conformations within 10 kcal.mole of the global
minimum and with a minimum RMSD between them of 0.5 Å. This conformational model was used as
the query to screen the Scopius database of commercially available molecules (InhibOx Ltd., Oxford,
UK). Scopius represents a consolidation of commercially available compounds from over 200 vendors

Molecules 2014, 19
16286
worldwide. Only the drug-like compounds in Scopius, 7.3 million, were included in the virtual screening
study. Drug-like compounds comply with Lipinski-like physicochemical properties and do not contain
substructures (represented as SMARTS patterns) known to be problematic for lead optimization. The
identified hits were ranked based on the ElecroShape score and 12 compounds of the top 100 hits were
purchased and tested for their NAT inhibition activity.
4. Conclusions
The piperidinol scaffold was identified as a selective prokaryotic NAT inhibitor that exhibits potent
antimycobacterial activity. The mechanism of inhibition of the NAT enzymes was confirmed previously
by mass spectroscopy analysis and X-ray 3D-structure determination of the MMNAT enzyme with
compound 1 [13]. The mechanism of NAT inhibition, which combines activation followed by covalent
modification, presents an attractive starting point for novel anti-tubercular agents. Whilst NAT has been
shown to be essential for intracellular survival of mycobacteria, it is likely that the piperidinols inhibit
mycobacterial growth via inactivation of other targets also. Considering both the concept of polypharmacy
and the resistance problems associated with TB treatment, more than one target is highly desirable.
In an attempt to improve antimycobacterial action and inhibition of NAT enzymic activity, we have
studied a series of analogues with selective structural modifications. We have tested antimycobacterial
actions on M. bovis BCG and M. tuberculosis and have used pure recombinant NAT enzymes from
M. marinum and M. tuberculosis. The halogenation of the para position of the benzene rings as well as
a hydrophobic N functionality showed improvement of the inhibition of MMNAT. The library of
piperidinols tested exhibit different activity against MMNAT and TBNAT, despite the high sequence
similarity between both enzymes. This is likely to be associated with the subtle differences in the
architecture of the binding pocket of MMNAT and TBNAT.
Two new scaffolds of NAT inhibitors have been identified in silico using the 3D-shape and
electrostatic modeling of compound 1 as a query molecule. The results demonstrate that the intact
piperidinols have structural complementarity to the binding pocket of MMNAT such that non-specific
affinity to the enzyme is excluded. Compound 15 identified through shape comparison was also
demonstrated to inhibit the growth of M. bovis BCG.
The results clearly highlight the importance of the piperidinol scaffold as a lead in antimicrobial drugs
development and underline the benefits of extending the number of new chemical entities through
in silico methods.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/19/10/16274/s1.
Acknowledgments
The authors thank Hilary Long for excellent technical assistance. We thank Siamon Gordon
(University of Oxford, UK) who generously donated the mouse macrophage cell line RAW 264.7.

Molecules 2014, 19
16287
Author Contributions
AA, EF, SB, PF carried out experiments and analysed data. AR and GM analysed data. ES
co-ordinated the research. AA, ES, PF wrote the paper. All authors approved the final manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Dye, C.; Williams, B.G. The population dynamics and control of tuberculosis. Science 2010, 328,
856–861.
2. WHO. Global Tuberculosis Report 2013. Available online: http://www.who.int/tb/publications/
global_report/gtbr13_executive_summary.pdf?ua=1 (accessed on 24 September 2014).
3. Sarkar, S.; Suresh, M.R. An overview of tuberculosis chemotherapy—A literature review.
J. Pharm. Pharm. Sci. 2011, 14, 148–161.
4. Shenoi, S.; Friedland, G. Extensively drug-resistant tuberculosis: A new face to an old pathogen.
Annu. Rev. Med. 2009, 60, 307–320.
5. Udwadia, Z.F.; Amale, R.A.; Ajbani, K.K.; Rodrigues, C. Totally drug-resistant tuberculosis in
India. Clin. Infect. Dis. 2012, 54, 579–581.
6. Rowland, K. Totally drug-resistant TB emerges in India: Discovery of a deadly form of TB
highlights crisis of “mismanagement”. Nat. News 2012, doi:10.1038/nature.2012.9797.
7. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H.W.; Neefs, J.M.; Winkler, H.;
van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; et al. A diarylquinoline drug active on the ATP
synthase of Mycobacterium tuberculosis. Science 2005, 307, 223–227.
8. Diacon, A.H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.;
Krause, R.; Bogoshi, M.; Churchyard, G.; et al. The diarylquinoline TMC207 for multidrug-resistant
tuberculosis. N. Engl. J. Med. 2009, 360, 2397–2405.
9. Osborne, R. First novel anti-tuberculosis drug in 40 years. Nat. Biotechnol. 2013, 31, 89–91.
10. Makarov, V.; Manina, G.; Mikusova, K.; Mollmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.;
Pasca, M.R.; Buroni, S.; Lucarelli, A.P.; et al. Benzothiazinones kill Mycobacterium tuberculosis
by blocking arabinan synthesis. Science 2009, 324, 801–804.
11. Kaneko, T.; Cooper, C.; Mdluli, K. Challenges and opportunities in developing novel drugs for TB.
Future Med. Chem. 2011, 3, 1373–1400.
12. Singh, J.; Petter, R.C.; Baillie, T.A.; Whitty, A. The resurgence of covalent drugs. Nat. Rev.
Drug Discov. 2011, 10, 307–317.
13. Abuhammad, A.; Fullam, E.; Lowe, E.D.; Staunton, D.; Kawamura, A.; Westwood, I.M.;
Bhakta, S.; Garner, A.C.; Wilson, D.L.; Seden, P.T.; et al. Piperidinols that show anti-tubercular
activity as inhibitors of arylamine N-acetyltransferase: An essential enzyme for mycobacterial
survival inside macrophages. PLoS One 2012, 7, e52790.

Molecules 2014, 19
16288
14. Bhakta, S.; Besra, G.S.; Upton, A.M.; Parish, T.; Sholto-Douglas-Vernon, C.; Gibson, K.J.;
Knutton, S.; Gordon, S.; DaSilva, R.P.; Anderton, M.C.; et al. Arylamine N-acetyltransferase is
required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and
represents a novel drug target. J. Exp. Med. 2004, 199, 1191–1199.
15. Anderton, M.C.; Bhakta, S.; Besra, G.S.; Jeavons, P.; Eltis, L.D.; Sim, E. Characterization of the
putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG.
Mol. Microbiol. 2006, 59, 181–192.
16. Yam, K.C.; D’Angelo, I.; Kalscheuer, R.; Zhu, H.; Wang, J.X.; Snieckus, V.; Ly, L.H.;
Converse, P.J.; Jacobs, W.R., Jr.; Strynadka, N.; et al. Studies of a ring-cleaving dioxygenase
illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis.
PLoS Pathog. 2009, 5, e1000344.
17. Suleyman, H.; Gul, H.I.; Asoglu, M. Anti-inflammatory activity of 3-benzoyl-1-methyl-4-phenyl-
4-piperidinol hydrochloride. Pharmacol. Res. 2003, 47, 471–475.
18. Vashishtha, S.C.; Allen, T.M.; Halleran, S.; Szydlowski, J.; Santos, C.L.; De Clercq, E.; Balzarani, J.;
Dimmock, J.R. Cytotoxic and anticancer properties of some 4-aryl-3-arylcarbonyl-1-ethyl-4-
piperidinols and related compounds. Pharmazie 2001, 56, 390–393.
19. Gul, H.I.; Calls, U.; Ozturk, Z.; Tutar, E.; Calikiran, L. Evaluation of anticonvulsant activities of
bis(3-aryl-3-oxo-propyl) ethylamine hydrochlorides and 4-aryl-3-arylcarbonyl-1-ethyl-4-piperidinol
hydrochlorides. Arzneim. Forsch. 2007, 57, 133–136.
20. Gul, H.I.; Sahin, F.; Gul, M.; Ozturk, S.; Yerdelen, K.O. Evaluation of antimicrobial activities of
several Mannich bases and their derivatives. Arch. Pharm. (Weinheim) 2005, 338, 335–338.
21. Jeney, E.; Zsolnai, T. Studies in search of new tuberculostatic drugs. I. Hydrazine derivatives, carbolic
acid, phenols, quaternary ammonium compounds and their intermediaries. Zentralbl. Bakteriol. Orig.
1956, 167, 55–64.
22. Sloan, K.B.; Koch, S.A.M.; Siver, K.G. Mannich base derivatives of theophylline and 5-fluorouracil:
Syntheses, properties and topical delivery characteristics. Int. J. Pharm. 1984, 21, 251–264.
23. Brooke, E.W.; Davies, S.G.; Mulvaney, A.W.; Pompeo, F.; Sim, E.; Vickers, R.J. An approach to
identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorg. Med. Chem. 2003,
11, 1227–1234.
24. Westwood, I.; Bhakta, S.; Russell, A.; Fullam, E.; Anderton, M.; Kawamura, A.; Mulvaney, A.;
Vickers, R.; Bhowruth, V.; Besra, G.; et al. Identification of aryalmine N-acetyltransferase inhibitors
as an approach towards novel anti-tuberculars. Protein Cell 2010, 1, 82–95.
25. Westwood, I.M.; Kawamura, A.; Russell, A.J.; Sandy, J.; Davies, S.G.; Sim, E. Novel small-molecule
inhibitors of arylamine N-acetyltransferases: Drug discovery by high-throughput screening.
Comb. Chem. High Throughput Screen. 2011, 14, 117–124.
26. Fullam, E. Arylamine N-Acetyltransferase of Mycobacteria. Ph.D. Thesis, Oxford University,
Oxford, UK, July 2007.
27. Abuhammad, A.M.; Lowe, E.D.; Fullam, E.; Noble, M.; Garman, E.F.; Sim, E. Probing the
architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site. Protein Cell
2010, 1, 384–392.
28. Kitz, R.; Wilson, I.B. Esters of methanesulfonic acid as irreversible inhibitors of
acetylcholinesterase. J. Biol. Chem. 1962, 237, 3245–3249.

Molecules 2014, 19
16289
29. PerkinElmer. Available online: http://www.cambridgesoft.com (accessed on 8 September 2014).
30. Fullam, E.; Kawamura, A.; Wilkinson, H.; Abuhammad, A.; Westwood, I.; Sim, E. Comparison of
the arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis.
Protein J. 2009, 28, 281–293.
31. Abuhammad, A. Arylamine N-acetyltransferases from Mycobacteria: Investigations of a Potential
Target for Anti-Tubercular Therapy. Ph.D. Thesis, University of Oxford, Oxford, UK, April 2013.
32. Fullam, E.; Westwood, I.M.; Anderton, M.C.; Lowe, E.D.; Sim, E.; Noble, M.E. Divergence of cofactor
recognition across evolution: Coenzyme a binding in a prokaryotic arylamine N-acetyltransferase.
J. Mol. Biol. 2008, 375, 178–191.
33. Pluvinage, B.; Sierra-Gallay, I.L.; Kubiak, X.; Xu, X.; Dairou, J.; Dupret, J.M.; Rodrigues-Lima, F.
The Bacillus anthracis arylamine N-acetyltransferase ((BACAN)NAT1) that inactivates
sulfamethoxazole, reveals unusual structural features compared with the other NAT isoenzymes.
FEBS Lett. 2011, 585, 3947–3952.
34. Abuhammad, A.; Lowe, E.D.; McDonough, M.A.; Stewart, P.D.S.; Kolek, S.A.; Sim, E.; Garman, E.F.
Structure of arylamine N-acetyltransferase from M. tuberculosis determined by cross-seeding with
homologous protein from M. marinum: Triumph over adversity. Acta Crystallogr. D 2013, in press.
35. Ballester, P.J.; Westwood, I.; Laurieri, N.; Sim, E.; Richards, W.G. Prospective virtual screening with
ultrafast shape recognition: The identification of novel inhibitors of arylamine N-acetyltransferases.
J. R. Soc. Interface 2010, 7, 335–342.
36. Armstrong, M.S.; Finn, P.W.; Morris, G.M.; Richards, W.G. Improving the accuracy of ultrafast
ligand-based screening: Incorporating lipophilicity into electroshape as an extra dimension.
J. Comput. Aided Mol. Des. 2011, 25, 785–790.
37. Armstrong, M.S.; Morris, G.M.; Finn, P.W.; Sharma, R.; Moretti, L.; Cooper, R.I.; Richards, W.G.
Electroshape: Fast molecular similarity calculations incorporating shape, chirality and electrostatics.
J. Comput. Aided Mol. Des. 2010, 24, 789–801.
38. Armstrong, M.S.; Morris, G.M.; Finn, P.W.; Sharma, R.; Richards, W.G. Molecular similarity
including chirality. J. Mol. Graph. Model. 2009, 28, 368–370.
39. Biovir. Available online: http://accelrys.com/products/discovery-studio/ (accessed on 8
September 2014).
40. Cwik, A.; Fuchs, A.; Hell, Z.; Clacens, J.-M. An efficient and environmental-friendly synthesis of
4-hydroxy-arylpiperidines using hydrotalcite catalyst. J. Mol. Catal. A Chem. 2004, 219, 377–381.
41. Payton, M.; Auty, R.; Delgoda, R.; Everett, M.; Sim, E. Cloning and characterization of arylamine
N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis:
Increased expression results in isoniazid resistance. J. Bacteriol. 1999, 181, 1343–1347.
42. Sinclair, J.C.; Sandy, J.; Delgoda, R.; Sim, E.; Noble, M.E. Structure of arylamine
N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 2000, 7, 560–564.
43. Westwood, I. Structure and Activity of Arylamine N-Acetyltransferase form Pseudomonas
aeruginosa; Oxford University: Oxford, UK, 2005.
44. Abuhammad, A.; Lack, N.; Schweichler, J.; Staunton, D.; Sim, R.B.; Sim, E. Improvement of the
expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase
(TBNAT) a potential target for novel anti-tubercular agents. Protein Expr. Purif. 2011, 80, 246–252.

Molecules 2014, 19
16290
45. Kawamura, A.; Graham, J.; Mushtaq, A.; Tsiftsoglou, S.A.; Vath, G.M.; Hanna, P.E.; Wagner, C.R.;
Sim, E. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by
high-throughput screening. Biochem. Pharmacol. 2005, 69, 347–359.
46. Wang, W.; Zhang, C.; Marimuthu, A.; Krupka, H.I.; Tabrizizad, M.; Shelloe, R.; Mehra, U.; Eng, K.;
Nguyen, H.; Settachatgul, C.; et al. The crystal structures of human steroidogenic factor-1 and liver
receptor homologue-1. Proc. Natl. Acad. Sci. USA 2005, 102, 7505–7510.
47. Evangelopoulos, D.; Bhakta, S. Rapid methods for testing inhibitors of mycobacterial growth. In
Antibiotic Resistance Protocols; Gillespie, S.H., McHugh, T.D., Eds.; Humana Press: New York,
NY, USA, 2010; Volume 642, pp. 193–201.
48. Russell, A.J.; Westwood, I.M.; Crawford, M.H.; Robinson, J.; Kawamura, A.; Redfield, C.;
Laurieri, N.; Lowe, E.D.; Davies, S.G.; Sim, E. Selective small molecule inhibitors of the potential
breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse
arylamine N-acetyltransferase 2. Bioorg. Med. Chem. 2009, 17, 905–918.
49. Yajko, D.; Madej, J.; Lancaster, M.; Sanders, C.; Cawthon, V.; Gee, B.; Babst, A.; Hadley, W.
Colorimetric method for determining mics of antimicrobial agents for Mycobacterium tuberculosis.
J. Clin. Microbiol. 1995, 33, 2324–2327.
50. Franzblau, S.G.; Witzig, R.S.; McLaughlin, J.C.; Torres, P.; Madico, G.; Hernandez, A.;
Degnan, M.T.; Cook, M.B.; Quenzer, V.K.; Ferguson, R.M.; et al. Rapid, low-technology mic
determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamar
blue assay. J. Clin. Microbiol. 1998, 36, 362–366.
51. Ebejer, J.-P.; Morris, G.M.; Deane, C.M. Freely available conformer generation methods: How
good are they? J. Chem. Inf. Model. 2012, 52, 1146–1158.
Sample Availability: Samples of the compounds are not available.
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).